Tue 23'rd May 2017
Esperion Therapeutics Stock Analysis
Technical stock analysis for Tue 23'rd May 2017
Sell candidate since 2017-05-23
Esperion Therapeutics lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 16.1% during the next 3 months and, with 90% probability hold a price between USD 33.05 and USD 53.31 at the end of this period.
A buy signal was issued from a pivot bottom point on Monday May 08, 2017, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Esperion Therapeutics holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at USD 35.17 and USD 36.39. A break-up above any of these levels will issue buy signals. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Relative Strength Index (RSI)
RSI14 is 31 and the stock is currently not being overbought or oversold
Support & Resistance
Esperion Therapeutics finds support from accumulated volume at USD 32.45, USD 30.44, and USD 26.17. On the upside the stock meets some resistance from accumulated volume at USD 39.05, USD 39.01 and USD 40.40.
This stock is usually traded at good volume, and with minor daily changes the risk is considered to be low. During the last day, the stock moved USD 1.19 (3.65%) between high and low. For the last week, the stock has had a daily average volatility of 6.16%.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
The stock stock holds several negative signals and despite the positive trend we believe Esperion Therapeutics will perform weak in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Hold/Accumulate to a Sell Candidate.